Kimberly Levering
Gerontology · Cincinnati, OHNPI 1629407531
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 35 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by Dexcom, Inc. at 30.0% of the total.
Across 35 payments — averaging $70.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dexcom, Inc.$736
- AstraZeneca$359
- Novo Nordisk$333
- BETA Bionics, Inc.$285
- Lilly USA, LLC$253
- Sequel Med Tech, LLC$231
- plus $253 from 4 others
What the payments were for
- Food & beverage$2,439100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dexcom, Inc. | 10 | $736 |
| AstraZeneca | 4 | $359 |
| Novo Nordisk | 4 | $333 |
| BETA Bionics, Inc. | 2 | $285 |
| Lilly USA, LLC | 6 | $253 |
| Sequel Med Tech, LLC | 2 | $231 |
| Xeris Pharmaceuticals, Inc. | 1 | $118 |
| Insulet Corporation | 2 | $71 |
| Amryt Pharma Holdings Ltd | 3 | $47 |
| Amgen | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- iLet Bionic Pancreas$855
- FARXIGA$344
- DEXCOM G6 TRANSMITTER$247
- TWIIST$138
- GVOKE HYPOPEN$118
How this compares
$2,451 in reported general payments places this provider in the 85th percentile of 361 gerontology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TradjentaLinagliptin | 20 | $10,877 |
| Tresiba Flextouch U-100Insulin Degludec | 16 | $7,563 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 15 | $3,158 |
| Novolog FlexpenInsulin Aspart | 15 | $2,791 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $1,785 |
| Ultra-Fine Short Pen NeedlePen Needle, Diabetic | 12 | $759 |
| Metformin Hcl ErMetformin Hcl | 13 | $58 |
Paid to pharmacies, not to this prescriber.
Other gerontology in Cincinnati
- Diana SutherlandCincinnati$32K
- John ShinnCincinnati$26K
- Amy MalmedahlCincinnati$11K
- Lauren GettelfingerCincinnati$8K
- Arianna WarfelCincinnati$7K
- Cheryl HerrleCincinnati$4K
- Jeanette MeyerCincinnati$3K
- Sunshine BarhorstCincinnati$2K
- Christopher GoddardCincinnati$2K
- Kathryn DinhCincinnati$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.